查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1579428

Batten 疾病市场：按产品类型、疾病类型、给药途径和最终用户 - 2025-2030 年全球预测

Batten Disease Market by Product, Type of Disease, Route of Administration, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年巴顿病市场价值为5,489万美元，预计2024年将达5,761万美元，复合年增长率为5.18%，到2030年将达7,819万美元。

巴顿病是一种罕见且致命的体染色体隐性神经退化性疾病，主要影响儿童，是由基因突变引起的，这些突变会损害细胞健康所需的某些酶的功能。了解 KEYWORD 的必要性在于其使人衰弱的性质和缺乏有效的治疗方法，这促使研究人员努力开发新的治疗策略。应用集中在基因疗法、酵素替代疗法和小分子药物。最终用途范围从医院和诊断中心到专门治疗神经系统疾病的专门治疗设施。由于意识的提高、基因研究的进步以及罕见疾病研究资金的增加，该市场正在不断增长。影响成长的关键因素包括诊断和治疗的技术进步以及对个人化医疗方法的日益重视。开发新疗法和改进诊断工具存在潜在的商机，公司应该投资研发来开拓这些领域。与学术机构的合作和参与临床试验可以加速进展。然而，这个市场面临局限性，包括研发成本高、对疾病病理生理学了解不足以及与孤儿药相关的监管挑战。患者数量少也是一个重大挑战，可能会阻碍大规模临床试验和商业化。业务成长的创新领域包括使用 CRISPR 技术进行基因编辑、基于先进生物标记的诊断，以及使用人工智慧进行药物发现和患者分层。此外，基因治疗和个人化医疗是有前景的研究和创新领域。市场的性质是专业化的，并由生物技术的进步所驱动。因此，公司必须注重以患者为中心的方法和策略伙伴关係关係，以最大限度地提高潜在利益。策略研究可能包括透过倡导团体来提高意识、参与合作研究以及考虑政府对孤儿药开发的激励措施，以成功驾驭这个利基市场。

主要市场统计
基准年[2023] 5489万美元
预测年份 [2024] 5761万美元
预测年份 [2030] 7819万美元
复合年增长率（%） 5.18%

市场动态：针对快速发展的巴顿病市场所揭示的关键市场见解

供需的动态交互作用正在改变巴顿病市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 提高对巴顿氏症的认识和诊断
    • 加大对罕见疾病研究的投入
    • 改善医疗基础设施和获取机会
  • 市场限制因素
    • 有限的临床试验资料和监管挑战
  • 市场机会
    • 创新治疗药物的开发
    • 基因组研究和个人化医疗的进展
  • 市场挑战
    • 疾病的复杂性和治疗方法的发展

波特五力策略工具驾驭巴顿病市场

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解对 Batten 疾病市场的外部影响

外部宏观环境因素在塑造巴顿病市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解巴顿氏症市场的竞争状况

对巴顿病市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵巴顿病市场供应商绩效评估

FPNV 定位矩阵是评估巴顿病市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了巴顿病市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对巴顿病市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高对巴顿氏症的认识和诊断
      • 加大对罕见疾病研究的投入
      • 改善医疗基础设施和获取机会
    • 抑制因素
      • 有限的临床试验资料和监管挑战
    • 机会
      • 开发创新治疗方法
      • 基因组研究和个人化医疗的进展
    • 任务
      • 疾病的复杂性和治疗方法的发展
  • 市场区隔分析
    • 产品：cerliponase alpha 在治疗上日益重要
    • 最终用户：医院环境中的多种应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章巴顿病市场：副产品

  • 药物
    • 丝脂酶α
    • 左乙拉西坦
    • 丙戊酸
  • 基因治疗

第 7 章 依疾病类型分類的巴滕疾病市场

  • 成人神经元蜡质脂褐质沉着症
  • 婴儿神经蜡质脂褐质沉着症
  • 幼年神经元蜡质脂褐质沉着症
  • 晚期婴儿神经蜡质脂褐质沉着症

第八章巴顿疾病市场：依给药途径

  • 静脉
  • 脑室内
  • 口服

第九章巴顿疾病市场：按最终用户

  • 家庭护理设置
  • 医院
  • 调查机构
  • 专科诊所

第10章美洲巴顿病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太巴顿病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲巴顿病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Latus Bio, Inc. 已获得 5,400 万美元的 A 轮资金筹措，旨在透过精准标靶化和更安全的管理彻底改变中枢神经系统基因治疗。
    • 罗彻斯特大学医学中心正在加强对抗巴顿病，并获得 NINDS 的 570 万美元资金来加速基因治疗试验。
  • 战略分析和建议

公司名单

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals Inc.
  • Amicus Therapeutics
  • BioMarin Pharmaceutical Inc.
  • Denali Therapeutics
  • Neurogene Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Passage Bio, Inc.
  • Regenxbio Inc.
  • Teva Pharmaceuticals Industries Ltd.
Product Code: MRR-B53D3ECDD928

The Batten Disease Market was valued at USD 54.89 million in 2023, expected to reach USD 57.61 million in 2024, and is projected to grow at a CAGR of 5.18%, to USD 78.19 million by 2030.

Batten Disease, a rare and fatal autosomal recessive neurodegenerative disorder, predominantly affects children and is caused by genetic mutations that impair the function of certain enzymes necessary for cell health. The necessity of understanding Batten Disease lies in its debilitating nature and the lack of effective treatment options, driving research efforts to develop novel therapeutic strategies. Application revolves around gene therapy, enzyme replacement therapy, and small molecule drugs. The end-use scope spans from hospitals and diagnostic centers to specialized treatment facilities focusing on neurological disorders. The market is witnessing growth due to increasing awareness, advances in genetic research, and rising funding for orphan disease research. Key factors influencing growth include technological advancements in diagnostics and therapeutics, coupled with a growing emphasis on personalized medicine approaches. Potential opportunities exist in the development of novel therapeutics and improved diagnostic tools; thus, companies should invest in R&D to explore these areas. Collaborative efforts with academic institutions and participation in clinical trials can accelerate advancements. However, the market faces limitations such as high R&D costs, limited understanding of the disease's pathophysiology, and regulatory challenges associated with orphan drugs. Another significant challenge is the small patient population, which can impede large-scale clinical trials and commercialization. Innovative areas for business growth include using CRISPR technology for gene editing, advanced biomarker-based diagnostics, and leveraging artificial intelligence for drug discovery and patient stratification. Moreover, gene therapy and personalized medicine represent promising arenas for research and innovation. The nature of the market is specialized and driven by advancements in biotechnology; hence, companies need to focus on patient-centric approaches and strategic partnerships to maximize potential benefits. Strategic recommendations include amplifying awareness through advocacy groups, engaging in collaborative research, and exploring government incentives for orphan drug development to successfully navigate this niche market.

KEY MARKET STATISTICS
Base Year [2023] USD 54.89 million
Estimated Year [2024] USD 57.61 million
Forecast Year [2030] USD 78.19 million
CAGR (%) 5.18%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Batten Disease Market

The Batten Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased awareness and diagnosis of batten disease
    • Rising investment in rare disease research
    • Improvement in healthcare infrastructure and access
  • Market Restraints
    • Limited clinical trial data and regulatory challenges
  • Market Opportunities
    • Development of innovative therapeutics
    • Advancements in genomic research and personalized medicine
  • Market Challenges
    • Complexity of disease and treatment development

Porter's Five Forces: A Strategic Tool for Navigating the Batten Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Batten Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Batten Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Batten Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Batten Disease Market

A detailed market share analysis in the Batten Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Batten Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Batten Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Batten Disease Market

A strategic analysis of the Batten Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Batten Disease Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals Inc., Amicus Therapeutics, BioMarin Pharmaceutical Inc., Denali Therapeutics, Neurogene Inc., Novartis AG, Orchard Therapeutics, Passage Bio, Inc., Regenxbio Inc., and Teva Pharmaceuticals Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Batten Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Drugs and Gene Therapy. The Drugs is further studied across Cerliponase Alfa, Levetiracetam, and Valproic Acid.
  • Based on Type of Disease, market is studied across Adult Neuronal Ceroid Lipofuscinosis, Infantile Neuronal Ceroid Lipofuscinosis, Juvenile Neuronal Ceroid Lipofuscinosis, and Late Infantile Neuronal Ceroid Lipofuscinosis.
  • Based on Route of Administration, market is studied across Intravenous, Intraventricular, and Oral.
  • Based on End-User, market is studied across Homecare Settings, Hospitals, Research Institutions, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased awareness and diagnosis of batten disease
      • 5.1.1.2. Rising investment in rare disease research
      • 5.1.1.3. Improvement in healthcare infrastructure and access
    • 5.1.2. Restraints
      • 5.1.2.1. Limited clinical trial data and regulatory challenges
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of innovative therapeutics
      • 5.1.3.2. Advancements in genomic research and personalized medicine
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity of disease and treatment development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising significance of cerliponase alfa in treatment
    • 5.2.2. End-User: Diverse scope of applications in hospital settings
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Batten Disease Market, by Product

  • 6.1. Introduction
  • 6.2. Drugs
    • 6.2.1. Cerliponase Alfa
    • 6.2.2. Levetiracetam
    • 6.2.3. Valproic Acid
  • 6.3. Gene Therapy

7. Batten Disease Market, by Type of Disease

  • 7.1. Introduction
  • 7.2. Adult Neuronal Ceroid Lipofuscinosis
  • 7.3. Infantile Neuronal Ceroid Lipofuscinosis
  • 7.4. Juvenile Neuronal Ceroid Lipofuscinosis
  • 7.5. Late Infantile Neuronal Ceroid Lipofuscinosis

8. Batten Disease Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Intraventricular
  • 8.4. Oral

9. Batten Disease Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals
  • 9.4. Research Institutions
  • 9.5. Specialty Clinics

10. Americas Batten Disease Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Batten Disease Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Batten Disease Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Latus Bio, Inc. secures USD 54 million series a funding to revolutionize CNS gene therapy with precision targeting and safer dosing
    • 13.3.2. University of Rochester medical center bolsters efforts in battling batten disease with USD 5.7 million NINDS funding to accelerate gene therapy trials
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alexion Pharmaceuticals Inc.
  • 3. Amicus Therapeutics
  • 4. BioMarin Pharmaceutical Inc.
  • 5. Denali Therapeutics
  • 6. Neurogene Inc.
  • 7. Novartis AG
  • 8. Orchard Therapeutics
  • 9. Passage Bio, Inc.
  • 10. Regenxbio Inc.
  • 11. Teva Pharmaceuticals Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BATTEN DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. BATTEN DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BATTEN DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BATTEN DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BATTEN DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BATTEN DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BATTEN DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BATTEN DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BATTEN DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BATTEN DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BATTEN DISEASE MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BATTEN DISEASE MARKET SIZE, BY CERLIPONASE ALFA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BATTEN DISEASE MARKET SIZE, BY LEVETIRACETAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BATTEN DISEASE MARKET SIZE, BY VALPROIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BATTEN DISEASE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BATTEN DISEASE MARKET SIZE, BY ADULT NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BATTEN DISEASE MARKET SIZE, BY INFANTILE NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BATTEN DISEASE MARKET SIZE, BY JUVENILE NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BATTEN DISEASE MARKET SIZE, BY LATE INFANTILE NEURONAL CEROID LIPOFUSCINOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BATTEN DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BATTEN DISEASE MARKET SIZE, BY INTRAVENTRICULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BATTEN DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BATTEN DISEASE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BATTEN DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. BATTEN DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. BATTEN DISEASE MARKET, FPNV POSITIONING MATRIX, 2023